going intracellular, page-3

Enumerate: I agree. To spinoff the endosome escape technology could be a smart move by PYC.
As we are aware, there have previously been a number of discussions with venture funds concerning investing in PYC.
I've been told, these investments didn't eventuate, due to:
1. venture funds preference to invest in privately held companies.
2. PYC's low sp in relation to the entry price a fund would be expected to pay.

To create a spinoff private company, that ticks all the boxes for venture fund investment, would see it valued on it's tech alone and would create potential for maximum funding with least dilution of PYC's stake.

I also agree with weedub's post, suggesting a new spinoff with Janssen would provide an immediate valuation point for the technology (though I wouldn't limit it to just Janssen funding).
SoT